ADAM, a non-hormonal male contraceptive, shows promise with a favorable safety profile and sustained efficacy in early trials. FDA updates testosterone product labels, removing cardiovascular risk ...
IsoPSA, a blood-based test, aids in diagnosing high-grade prostate cancer by analyzing PSA protein structural variants. FDA approval was based on a large-scale, prospective study and other validation ...
Non-muscle invasive bladder cancer treatments have expanded beyond BCG, offering alternatives to radical cystectomy with flexible dosing and scheduling. Muscle-invasive bladder cancer management is ...
In this debut episode of The UroOnc Minute, host Adam Weiner, MD, a urologic oncologist and surgeon-scientist at Cedars-Sinai Medical Center, introduces listeners to a new Urology Times podcast ...
Belzutifan, pembrolizumab, and lenvatinib combination showed superior efficacy in advanced ccRCC, with high overall response rates and prolonged progression-free survival. Arm 4 demonstrated a median ...
The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...
Cretostimogene grenadenorepvec shows a 24-month complete response rate of 41.8% in high-risk BCG-unresponsive patients with NMIBC, with 90% of 12-month responders maintaining CR. The BOND-003 trial ...
The updated guideline emphasizes a patient-centered, risk-based approach, prioritizing symptom resolution and antimicrobial stewardship over microbial eradication. New recommendations include ...
Detalimogene voraplasmid is a non-viral gene therapy for high-risk NMIBC, aiming to elicit an anti-tumor immune response. The LEGEND trial's pivotal cohort has enrolled 100 patients, with updates ...
AI tools like PathomIQ can predict prostate cancer metastasis by analyzing whole-slide images, independent of Gleason scores and gene expression profiling. Current AI applications in prostate cancer ...
Neuspera's iSNM system provides a battery-free alternative to traditional SNM, reducing complications and surgeries for UUI patients. The SANS-UUI trial showed 84.2% of patients achieved at least a 50 ...
Kidney stone prevalence in US adults is stable, but significantly increased among women, especially those under 60. Obesity, metabolic syndrome, and improved healthcare access may contribute to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback